IDXX logo

IDEXX Laboratories Inc. (IDXX)

$690.24

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IDXX

Market cap

$54.38B

EPS

14.84

P/E ratio

36.4

Price to sales

8.96

Dividend yield

--

Beta

1.545653

Price on IDXX

Previous close

$700.65

Today's open

$701.14

Day's range

$687.72 - $706.76

52 week range

$500.61 - $769.98

Profile about IDXX

CEO

Jonathan J. Mazelsky

Employees

11000

Headquarters

Westbrook, ME

Exchange

Nasdaq Global Select

Shares outstanding

78786265

Issue type

Common Stock

IDXX industries and sectors

Healthcare

Medical Diagnostics & Screening

News on IDXX

3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance

The Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength over the last month, with each raising also guidance in one way or another.

news source

Zacks Investment Research • Nov 17, 2026

news preview

3 Reasons Growth Investors Will Love Idexx (IDXX)

Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

news source

Zacks Investment Research • Nov 6, 2026

news preview

IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class

IDEXX Laboratories delivered strong Q3 results, beating expectations with 9.86% organic revenue growth and raising full-year revenue and EPS guidance. I maintain my buy rating on IDXX, citing its best-in-class diagnostics, high recurring revenue, and robust innovation pipeline supporting premium valuation. CoVet acquisition adds high-margin, AI-driven workflow software, enhancing stickiness and cross-selling, with a calculated purchase price near $223 million and double-digit growth potential.

news source

Seeking Alpha • Nov 4, 2026

news preview

IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)

IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward revision of FY26 revenue guidance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.

news source

Seeking Alpha • Nov 4, 2026

news preview

Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

news source

Zacks Investment Research • Nov 3, 2026

news preview

IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund

Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.

news source

24/7 Wall Street • Nov 2, 2026

news preview

IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction

IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. The higher 2026 profit forecast doesn't come from testing demand.

news source

The Motley Fool • Nov 2, 2026

news preview

Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move?

Idexx Laboratories outperformed a shaky macro on Monday, beating third-quarter forecasts. Idexx stock surged.

news source

Investors Business Daily • Nov 2, 2026

news preview

IDEXX raises forecast, betting diagnostics can offset weak vet visits

IDEXX Laboratories beat quarterly estimates and raised its annual profit and revenue forecast on Monday, betting ​that rising diagnostic use per visit and new ‌product launches will sustain growth through softer veterinary clinic traffic.

news source

Reuters • Nov 2, 2026

news preview

IDEXX Laboratories Q3 Earnings Call Highlights

IDEXX Laboratories NASDAQ: IDXX reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook.

news source

MarketBeat • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in IDEXX Laboratories Inc.

Open an M1 investment account to buy and sell IDEXX Laboratories Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IDXX on M1